Neos Therapeutics (NASDAQ:NEOS) Stock Price Up 5.1%

Neos Therapeutics Inc (NASDAQ:NEOS)’s stock price rose 5.1% on Friday . The stock traded as high as $1.93 and last traded at $1.85, approximately 303,953 shares changed hands during mid-day trading. A decline of 21% from the average daily volume of 384,034 shares. The stock had previously closed at $1.76.

NEOS has been the topic of several research reports. BMO Capital Markets decreased their price target on shares of Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating on the stock in a research note on Monday, August 12th. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald decreased their price target on shares of Neos Therapeutics from $20.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 12th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $6.05.

The company has a debt-to-equity ratio of 41.70, a quick ratio of 1.27 and a current ratio of 1.13. The business’s 50 day simple moving average is $1.43 and its 200 day simple moving average is $1.92.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Thursday, August 8th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The firm had revenue of $15.64 million for the quarter, compared to analysts’ expectations of $16.70 million. As a group, equities analysts predict that Neos Therapeutics Inc will post -0.5 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA raised its stake in Neos Therapeutics by 1,749.5% during the first quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock worth $26,000 after purchasing an additional 9,552 shares during the period. Alambic Investment Management L.P. purchased a new position in Neos Therapeutics during the first quarter worth about $32,000. Weiss Asset Management LP purchased a new position in Neos Therapeutics during the second quarter worth about $36,000. Acadian Asset Management LLC purchased a new position in Neos Therapeutics during the second quarter worth about $40,000. Finally, Jane Street Group LLC purchased a new position in Neos Therapeutics during the fourth quarter worth about $62,000. 54.88% of the stock is currently owned by institutional investors.

Neos Therapeutics Company Profile (NASDAQ:NEOS)

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

See Also: What is meant by holder of record?

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.